November 2024 Part C rule: 20pp about LCDs and NCDs

 Inspection copy 354-372 (Section U, Internal Policies) and corresponding regs at 629-631.   

November 26, 2024, inspection copy.

Main blog, https://www.discoveriesinhealthpolicy.com/2024/11/cms-policy-for-artificial-integence-in.html

The main blog focuses on AI sections.  This AI summary is based on the entirety of Section U (medical review transparency).  

AI CHAT GPT 4o follows.

##

[Section U]

The CMS proposed rule for Medicare Advantage (MA) plans introduces significant updates to the use of internal coverage criteria and automated systems, with an overarching focus on transparency, equity, and compliance. This regulatory shift reflects CMS's effort to standardize coverage determinations across MA plans while curbing potential misuse of internal algorithms and automation.

Key Aspects of the New Regulations

1. Enhanced Definition of Internal Coverage Criteria:

   • Internal coverage criteria are defined as any policies, measures, tools, or guidelines used by MA plans that are not explicitly stated in Medicare statutes, regulations, National Coverage Determinations (NCDs), or Local Coverage Determinations (LCDs). These criteria are often used to supplement or interpret Medicare rules when coverage details are incomplete​.
   • MA plans must now label, justify, and make publicly available all internal coverage criteria applied during medical necessity determinations, ensuring transparency​.

2. Limits on the Use of Automated Systems:

   • Automated systems, including those powered by artificial intelligence, must comply with strict transparency and compliance standards. Algorithms must be explicitly linked to evidence-based criteria, and plans must identify any embedded internal coverage criteria used in automated decision-making​.
   • CMS explicitly warns against the risk of algorithmic bias and emphasizes that MA organizations remain fully responsible for ensuring that automated systems align with Medicare regulations and contractual obligations​.

3. Prohibitions on Certain Internal Coverage Practices:

   • CMS prohibits the use of internal criteria that:
     • Lack demonstrable clinical benefit, such as those intended solely to reduce service utilization​.
     • Enforce blanket denials of coverage without individualized medical necessity reviews​.

4. Public Accessibility Requirements:

   • MA organizations must post internal coverage criteria, supporting evidence, and explanations of their adoption on publicly accessible websites. The rule strengthens expectations for readability and transparency to ensure beneficiaries and stakeholders can easily access and understand the criteria​.

5. Focus on Patient Safety:

   • CMS encourages MA plans to replace vague claims of clinical benefit with clear, evidence-based demonstrations of how internal criteria enhance patient safety​.

---

Critical Discussion: Balancing Oversight with Innovation

Strengths of the Proposed Rule

1. Equity and Transparency:

   • The emphasis on transparency addresses concerns about hidden coverage decisions and arbitrary denials. By requiring public posting of internal criteria, CMS fosters accountability and allows stakeholders to scrutinize the rationale behind coverage determinations.

2. Safeguards Against Bias:

   • The strict oversight of automated systems mitigates risks of discrimination or inequitable treatment arising from poorly designed or biased algorithms.

3. Consistency with Traditional Medicare:

   • Aligning MA coverage policies more closely with Traditional Medicare ensures that MA enrollees receive equitable access to benefits. This move curtails deviations caused by proprietary internal coverage criteria.

Challenges and Potential Drawbacks

1. Administrative Burdens:

   • MA plans face significant costs and logistical hurdles in complying with the new transparency and auditing requirements. Smaller plans may struggle to adapt, potentially reducing market competition.

2. Impact on Innovation:

   • The restrictions on automated systems and internal criteria could stifle technological innovation. MA plans might hesitate to invest in advanced AI-driven tools if compliance risks outweigh potential benefits.

3. Ambiguity in Compliance Standards:

   • The new standards for proving clinical benefit and patient safety require further clarification. Without clear metrics, MA plans may face uncertainty in justifying their criteria.

4. Trade Secrets and Proprietary Tools:

   • Publicizing internal coverage criteria may inadvertently expose proprietary methodologies, undermining competitive advantages and disincentivizing innovation.

---

Implications for MA Organizations

For MA plans, particularly those leveraging advanced AI and automation:

• Proactive Compliance: Plans must audit existing algorithms, identify embedded internal criteria, and ensure alignment with CMS’s evidentiary and transparency standards.
• Collaborative Engagement: Engaging with CMS during the comment period can shape practical implementation guidelines, particularly for demonstrating patient safety and clinical benefit.
• Strategic Adaptation: Plans should balance compliance with innovation by prioritizing tools that offer clear patient-centered benefits while minimizing operational complexities.

---

In conclusion, while CMS’s proposed rule seeks to enhance equity and consistency in Medicare Advantage, its success hinges on achieving a balance between regulatory oversight and fostering technological innovation. Lawmakers and stakeholders must carefully weigh these considerations to avoid unintended consequences that could limit access to improved care through innovative AI applications.

Statute: No Retroactive Medicare Rules SSA 1871

 I believe there's a remark in the Medicare statute (Social Security Act) that Medicare (or CMS) can't make retroactive rules and policies and regulations.

[This is in addition to a remark in the Constitution that federal laws [and state laws] can't be ex post factor.]

Chat GPT

SSA 1871

Yes, the Medicare statute includes provisions that generally prohibit the Centers for Medicare & Medicaid Services (CMS) from applying substantive changes to regulations, manual instructions, interpretative rules, statements of policy, or guidelines retroactively. 

Specifically, Section 1871(e)(1)(A) of the Social Security Act states:

"A substantive change in regulations, manual instructions, interpretative rules, statements of policy, or guidelines of general applicability under this subchapter shall not be applied (by extrapolation or otherwise) retroactively to items and services furnished before the effective date of the change, unless the Secretary determines that— (i) such retroactive application is necessary to comply with statutory requirements; or (ii) failure to apply the change retroactively would be contrary to the public interest."

This means that CMS is generally prohibited from applying substantive changes retroactively unless one of the two specified exceptions is met:

1. Compliance with Statutory Requirements: If retroactive application is necessary to comply with statutory mandates.

2. Public Interest: If not applying the change retroactively would be contrary to the public interest.

These exceptions are intended to be narrowly construed to prevent undue hardship on providers and beneficiaries due to unexpected retroactive policy changes.

Mondaq

The prohibition against retroactive rulemaking in the Medicare context was notably addressed in the Supreme Court case Bowen v. Georgetown University Hospital, 488 U.S. 204 (1988). In this case, the Court held that agencies do not have the authority to promulgate retroactive rules unless Congress has expressly granted such power. The Court emphasized that statutory grants of rulemaking authority should not be interpreted to authorize retroactive rulemaking unless that power is conveyed explicitly.

Wikipedia

Therefore, while the Medicare statute generally prohibits retroactive rulemaking, CMS may apply changes retroactively in specific circumstances where it is necessary to comply with statutory requirements or to serve the public interest, as determined by the Secretary.

###

Does something in the Constitution say that laws can't be retroactive? I think in old timey language.

ChatGPT said:

Yes, the Constitution addresses retroactive laws in what might seem like "old-timey language." Specifically, it prohibits two types of retroactive laws:

---

Ex Post Facto Laws

• Article I, Section 9, Clause 3 (for federal laws):
  "No Bill of Attainder or ex post facto Law shall be passed."

• Article I, Section 10, Clause 1 (for state laws):
  "No State shall pass any Bill of Attainder, ex post facto Law, or Law impairing the Obligation of Contracts..."

Meaning:
An ex post facto law retroactively makes an action illegal that was legal when it was committed, or increases the penalties for a crime after it was committed. This prohibition ensures fairness and prevents governments from punishing people for actions that were not against the law at the time.

---

Bills of Attainder

A related clause in the same sections prohibits Bills of Attainder. These are laws that single out individuals or groups for punishment without a trial, which can also have retroactive implications.

---

Key Example of the Language's Intent:

The Founders were deeply influenced by their distrust of arbitrary power, particularly abuses seen in British law. Retroactive laws were seen as tools of tyranny and injustice. By prohibiting ex post facto laws, the Constitution establishes a baseline of fairness and predictability in the legal system.

---

Note:
While these provisions prevent retroactive criminal laws, retroactive civil laws (e.g., changes to tax policy or contract rules) are not necessarily forbidden. Courts often scrutinize such laws to ensure they do not violate other constitutional principles, such as due process.

3 RUC Criticisms (2013, 2013, 2018) and AMA Rebuttal (2018)

 SIDEBAR TO NOVEMBER 21 BLOG on STAT, WAPO, and AMA

The new effort may harvest earlier thinking in this space.  See, Center for Public Integrity (2010), "Little-Known AMA Group...".  See Fuchs, SLU Journal of Health Law (2013), Medicare Price Problems.  See Center for American Progress (2018), Rethinking the RUC.  But see AMA (2018), Criticism of RUC Needs Rethinking.

###

AI CORNER

Chat GPT4 reviews the four articles.

###

Summary of the Articles Critiquing the AMA RUC:

1. "Medicare Price Problems and the RUC: Wagging the Dog" (2013)​

This article critiques the RUC's outsized influence on Medicare's payment decisions, highlighting that it operates outside the purview of the Federal Advisory Committee Act (FACA), which limits transparency and accountability. The RUC is seen as favoring procedural specialties over primary care, exacerbating payment disparities. The methodology, relying heavily on physician surveys with small sample sizes and potential biases, leads to systemic undervaluation of cognitive services and overvaluation of procedural work. Courts have been unable to review RUC's processes, further insulating it from reform.

2. "Little-Known AMA Group" (2013)​

This article describes the RUC as a secretive committee that heavily influences Medicare payment rates, accepting over 90% of its recommendations. Critics argue the RUC is dominated by specialists who prioritize high-tech procedures over primary care. It highlights structural issues such as secret voting and lack of public accountability, which foster conflicts of interest. Family physicians feel underrepresented, resulting in a primary care payment gap. Although the AMA defends the RUC as an independent panel advocating for fair representation, critics claim the process remains opaque and skewed toward specialties.

3. "Rethinking the RUC" (2018)​

This report emphasizes systemic flaws in the RUC's valuation process, particularly its reliance on subjective and biased survey data from specialty societies. It argues the RUC undervalues cognitive and primary care services while overvaluing procedural work due to the inherent conflicts of interest of its members. It criticizes the committee's lack of transparency, its small and insular membership, and the overall misalignment between its recommendations and the needs of the healthcare system, particularly the shift towards value-based care. Reform is deemed essential but politically challenging due to the AMA's resistance.

---

AMA’s Rebuttal: "Conventional Wisdom on Criticism of RUC Needs Rethinking" (2018)​

The AMA defends the RUC against these criticisms, arguing that while there may be some bias, the committee provides valuable, informed recommendations. The rebuttal cites research showing that any bias is slight and that shared affiliations among specialties contribute to more informed decisions. It highlights the RUC’s steps to improve transparency, such as publishing voting records and reviewing outdated procedures to redistribute $5 billion in payments. The AMA claims the RUC’s influence benefits primary care through shared interests and consensus-building efforts.

---

Comparison and Evaluation:

Comparison of Critiques:

• Transparency: All critiques emphasize the RUC’s opacity, citing secretive voting and limited public accountability. The AMA counters with claims of improved transparency but critics argue these steps are insufficient.
• Bias: Critics claim the RUC is dominated by specialists, leading to skewed payment recommendations favoring procedural work over primary care. The AMA acknowledges some bias but contends it is minor and mitigated by consensus and shared affiliations.
• Methodology: Critics highlight reliance on flawed survey data, small sample sizes, and inflated estimates. The AMA defends the surveys as essential tools, moderated through review and comparison processes.

Evaluation of AMA's Rebuttal:

The AMA’s defense is partially effective but not entirely convincing:

• Strengths: The AMA provides data suggesting the RUC’s influence benefits the system, highlights redistributive efforts, and addresses steps to improve transparency.
• Weaknesses: Critics’ points about systemic undervaluation of cognitive care and conflicts of interest remain inadequately addressed. Transparency measures, while improved, do not fully resolve concerns about secrecy or accountability. The defense relies on a narrow interpretation of bias, ignoring broader structural issues in the valuation process.

In conclusion, while the AMA effectively showcases the RUC’s contributions and reforms, it underestimates the depth of the systemic issues highlighted by critics. Further independent oversight and broader structural changes might be necessary to address the persistent concerns.

Leder-Luis on Fraud, Wisconsin October 2024

 

Chat GPT summary of Leder-Luis lecture, Wisconsin, October 2024

https://www.youtube.com/watch?v=QDVZRdm9aF8

Prof. Leder-Luis, an economist and assistant professor at Boston University, delivered a lecture on healthcare fraud, focusing on systemic issues within Medicare and Medicaid. The U.S. government spends over $1 trillion annually on health insurance, and fraud spans numerous sectors, including ambulances, pharmacies, and nursing homes. Fraud diverts resources from critical social programs, undermining their effectiveness and efficiency.

Key points from the lecture include:

1. Fraud Overview: Fraud in healthcare often arises from information asymmetry, where providers exploit their greater knowledge of services and patient needs. Examples include unnecessary services or overbilling.

2. Prior Research: Prof. Leder-Luis's studies emphasize enforcement mechanisms like whistleblower programs and prior authorization, showing their deterrence effects. However, his latest focus is on market design, questioning whether system structures incentivize fraud.

3. Ambulance Fraud: In a prior study, he highlighted fraudulent ambulance companies billing Medicare for unnecessary non-emergency dialysis transport. This showcased how fixed, inflated prices in healthcare incentivize exploitation.

4. Price Competition: The new study examines whether introducing competitive bidding in Medicare Durable Medical Equipment (DME) markets can reduce fraud. Competitive bidding was intended to lower costs and disincentivize fraudulent behavior.

5. Findings:

   • Competitive bidding reduces overall spending and prices but leads to unintended consequences.
   • Fraudulent firms gained market share due to their ability to operate at lower costs, potentially because of lower quality or unethical practices.
   • Legitimate firms were disproportionately affected, undermining the program's goals.

6. Mechanisms:

   • Larger firms, often fraudulent, thrive under competitive pressure, suggesting a selection bias.
   • Anti-competitive behaviors, such as collusion in bidding, may also play a role.
   • Reduced prices may indirectly encourage fraudulent practices by making honesty less profitable.

7. Implications: The lecture emphasized the need to balance price competition with mechanisms that prevent fraud and ensure quality. Prof. Leder-Luis advocates for systemic reforms to address these challenges.

This research offers insights into the complexity of reducing fraud in public healthcare programs while maintaining their integrity and effectiveness.

##

In more detail please.

##

Summary of Prof. Leder-Luis’s Lecture on Healthcare Fraud

Prof. Leder-Luis, an assistant professor at Boston University and an economist specializing in public program efficiency and healthcare fraud, discussed systemic challenges in combating fraud within Medicare and Medicaid, focusing particularly on market design and the role of competition. The lecture, titled "Competition and Fraud in Healthcare," highlighted how fraud manifests, its roots in system incentives, and the implications of policy measures aimed at curbing it.

Fraud in the Healthcare Sector

The U.S. government spends over $1 trillion annually on Medicare and Medicaid. Fraud, a pervasive issue across multiple sectors—such as ambulances, durable medical equipment (DME), and pharmacies—represents a significant inefficiency. Fraud diverts resources from underfunded social safety net programs, such as Medicaid, thereby undermining their intended purpose. Unlike waste, fraud involves deliberate deception, including billing for unnecessary or nonexistent services and equipment.

Prof. Leder-Luis emphasized the economic underpinning of healthcare fraud as an information asymmetry problem, where providers exploit their superior knowledge of patient needs and medical services relative to insurers. This creates incentives to engage in fraudulent activities, especially given the profit opportunities in certain segments of healthcare.

The Role of Market Design and Competition

Traditional enforcement mechanisms, such as whistleblower lawsuits, prepayment reviews, and ex-post investigations, have demonstrated varying degrees of success in deterring fraud. However, these approaches primarily address fraud after it occurs rather than examining its systemic origins. Prof. Leder-Luis’s recent work shifts focus to the structural conditions enabling fraud, asking whether changes to healthcare market design could mitigate fraudulent behavior preemptively.

One focal point of the lecture was the Medicare DME program, a $5–10 billion annual program covering products like wheelchairs, oxygen equipment, and hospital beds. Historically plagued by high levels of fraud—evidenced by improper payment rates exceeding 20%—DME fraud involves schemes such as billing for unnecessary equipment or inflating the cost of provided items (upcoding). For example, fraudulent suppliers might deliver high-cost wheelchairs to patients who do not need them, supported by dubious physician prescriptions.

In response, Medicare implemented competitive bidding for DME. By introducing price competition, the program aimed to lower prices and reduce fraud by decreasing profit margins that incentivize unethical behavior.

Key Research Findings

Prof. Leder-Luis and his team analyzed the effects of competitive bidding on fraud using Medicare claims data and a difference-in-differences methodology, leveraging the staggered rollout of competitive bidding across regions. Their findings reveal significant unintended consequences:

1. Overall Spending and Price Reductions:

   • Competitive bidding successfully reduced total spending, prices, and quantities of DME.
   • This aligns with prior literature showing that competitive bidding lowers costs and curtails oversupply.

2. Market Dynamics and Fraud:

   • Contrary to expectations, fraudulent firms gained market share under competitive bidding. These firms often operate at lower costs, potentially by sacrificing quality or engaging in unethical practices, allowing them to outbid legitimate firms.
   • Legitimate firms were disproportionately disadvantaged, suggesting that the competitive bidding process inadvertently selected for firms willing to cut corners.

3. Mechanisms Driving Fraud:

   • Firm Size Effects: Larger firms, which may include fraudulent operators, are better equipped to absorb the overhead costs associated with competitive bidding and compliance requirements. This structural advantage may explain their resilience.
   • Anti-Competitive Behavior: Some fraudulent firms may engage in collusive practices or exploit weaknesses in auction systems to gain a competitive edge.
   • Cost and Quality Trade-offs: Fraudulent firms may reduce costs by lowering quality or bypassing regulations, enabling them to survive and thrive in a price-competitive environment.

Broader Implications

The research underscores the complexity of designing fraud-resistant systems. While competitive bidding reduces program costs, it creates perverse incentives that allow unethical firms to dominate the market. This finding challenges the assumption that competition alone can improve market efficiency and highlights the importance of balancing price reduction strategies with safeguards against fraud.

Prof. Leder-Luis situated this study within broader literatures on healthcare fraud, market competition, and public goods provision. He emphasized the need for policies that address the root causes of fraud, such as regulatory gaps and inadequate oversight mechanisms, rather than relying solely on reactive enforcement.

Conclusion

Prof. Leder-Luis concluded by advocating for a nuanced approach to combating healthcare fraud. Policymakers must weigh the trade-offs between lowering costs and ensuring program integrity, considering both the structural incentives for fraud and the characteristics of firms that succeed in competitive environments. This research offers critical insights into how public programs can be designed to minimize fraud while preserving their social welfare objectives.

RFK Jr on Chronic Disease (YouTube, 2 minutes)

Auto transcript

https://www.youtube.com/watch?v=Avt5z1WT7eA

RFK Jr  

4% of our GDP went to health care when my uncle was president. 

Today, 20% does. It's $4.3 trillion.  Our entire defense budget, including national security veterans, everything is 1.3 trillion. 

Health care is $4.3T and 93% of Medicare claims are for chronic disease. 6% of kids had chronic disease when my uncle is present, 60% today. 

Nobody's saying anything. 

These are all autoimmune diseases, which I never heard of, rheumatoid arthritis, juvenile diabetes, these exotic Crohn's disease, lupus. 

I have a lot of young people in my audience. Almost all of them have something. It's hard to find a young person who does not have neuro developmental disorders add ADHD, speech related language like tics, Rett syndrome, ASD, autism, our kids are all on Adderall. They're all on SSRIs.

Why?  Doctors didn't just start prescribing these for no reason. We have damaged this entire generation. We have poisoned them. 

And the autism rates have gone from one in 10,000 in my generation 70 year old men, one in 10,000 of people my age has autism. One in every 34 kids in my kids generation, one in every 22 boys. The military can't recruit kids anymore. They're so badly damaged. And it's bankrupting our country, and it's rising exponentially.

And nobody is mentioning it> We we have a medical cartel which are our regulatory agencies, the pharmaceutical companies, the doctors, hospitals, that which are all owned by hedge funds, are now making a killing on chronic disease. And the sicker we get, the richer they get. 

The insurance industry, the sicker we are, the richer they are and nobody is saying anything. 

No, not one presidential candidate ever mentions this. It's the biggest issue.

Transcribed by https://otter.ai

Universal CGP in Lung Cancer: Comparing MENG (2024) and DOWDELL (2024)

 See a discussion of DOWDELL at ASCO Daily News.

https://dailynews.ascopubs.org/do/comprehensive-genomic-profiling-improves-precision-therapy-use-and-patient-survival

Here are the citations to MENG and to DOWDELL.  MENG looks at CGP in lung cancer, DOWDELL looks at CGP across solid cancers.

Here are the citations for each paper in a standard format:

1. Meng, R., Dowdell, A. K., Vita, A., Hanes, D., Bapat, B., Chang, S.-C., Harold, L., Schmidt, M., Wong, C., Poon, H., Schroeder, B., Weerasinghe, R., Sanborn, R., Leidner, R., Urba, W. J., Bifulco, C., & Piening, B. (2024). Clinical impact for advanced non-small-cell lung cancer patients tested using comprehensive genomic profiling at a large USA health care system. ESMO Real World Data and Digital Oncology, Volume 5, Issue C. https://doi.org/10.1016/j.esmorw.2024.100057.

2. Dowdell, A. K., Meng, R. C., Vita, A., Bapat, B., Hanes, D., Chang, S.-C., Harold, L., Wong, C., Poon, H., Schroeder, B., Weerasinghe, R., Leidner, R., Urba, W. J., Bifulco, C., & Piening, B. D. (2024). Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health system. JCO Oncology Practice, 20(11), 1523-1532. https://doi.org/10.1200/OP.24.00226.

Here is an AI comparision of the two papers.

The two studies by Meng et al. and Dowdell et al. focus on the clinical impact of comprehensive genomic profiling (CGP) for cancer patients, particularly in non-small cell lung cancer (NSCLC) and advanced solid tumors, using Providence Health System’s in-house CGP protocol. Here’s a PhD-level comparative analysis and overlap assessment:

1. Research Context and Objectives:
   Both studies aim to assess the effectiveness of in-house CGP on treatment outcomes and precision therapy adoption. Meng et al. focus specifically on advanced NSCLC patients, comparing outcomes between CGP-tested patients and those using a prior 50-gene small panel. Dowdell et al. take a broader approach by implementing pathologist-directed CGP testing across various tumor types and stages, with an emphasis on precision therapy adoption and overall survival benefits.

2. Methodology and Cohorts:

   • Meng et al. assess NSCLC patients with a targeted comparison between those tested with CGP versus a prior small panel, concentrating on actionable biomarker detection and therapy alignment. Their CGP panel (ProvSeq 523 genes) was implemented to capture actionable mutations, especially in NSCLC, using a structured approach with additional PD-L1 and TMB biomarker analysis.
   • Dowdell et al., by contrast, standardize CGP testing across all advanced cancers in a broader patient cohort (3,216 cases), with a focus on universal adoption through a pathologist-directed protocol immediately at diagnosis. They also explore clinical trial eligibility as a metric for treatment efficacy. While both studies use the same CGP panel, Dowdell’s study includes a broader in silico comparator cohort to estimate outcomes based on a 50-gene panel.

3. Data Collection and Analysis Techniques:
   Both studies employ natural language processing (NLP) tools to extract PD-L1 results from pathology notes, achieving high precision and recall, which enhances consistency in biomarker reporting.   However, Dowdell et al. adopt additional machine-learning-based chart mining across a more diverse tumor registry dataset, thus allowing for a more comprehensive analysis of various tumor types and treatment modalities.

4. Results – Actionable Biomarkers and Therapy Outcomes:

   • In Meng et al., CGP testing led to actionable biomarkers in 77% of NSCLC cases, with a significant survival advantage (median OS of 15.7 months for CGP versus 7 months for small panel). CGP testing increased precision therapy usage from 50% to 64%, with a higher rate of TT utilization.
   • Dowdell et al. report that 49% of all advanced cancer cases had at least one actionable biomarker, and CGP expanded eligibility for precision therapy by broadening access to trials. They found that CGP-tested patients with actionable markers had a 52% rate of TT or IO usage, with improved OS (25 months for TT versus 17 months for chemotherapy alone).

5. Overlap and Novel Contributions:
   Both studies overlap in highlighting CGP’s value in expanding treatment options and survival outcomes. However, Meng et al. provide a narrower focus on NSCLC and the CGP panel’s ability to detect mutations previously missed by small panels. Dowdell et al. expand this by applying CGP across a diverse range of cancers and emphasizing a system-wide protocol that standardizes CGP from the diagnostic stage, aiming to reduce barriers to testing and improve workflow efficiency.

6. Conclusions and Implications:
   Both papers underscore CGP’s efficacy in promoting precision medicine and improving patient survival. Meng et al.’s findings are particularly compelling for NSCLC clinical protocols, while Dowdell et al. suggest that pathologist-directed CGP testing could become a standard in cancer care, highlighting broader, system-level changes in oncology practice.

In summary, the studies provide complementary perspectives, with Meng et al. focused on deep insights into NSCLC patient outcomes, and Dowdell et al. highlighting systemic protocol shifts and broader population impacts. This synthesis supports the push toward CGP standardization in oncology but points to specific improvements in protocol, turnaround time, and physician engagement to achieve widespread, effective CGP implementation.

Califf at Milken Institute, November 13, 2024

Event 

https://milkeninstitute.org/content-hub/event-panels/part-1-conversation-fda-commissioner-robert-califf-1

Transcript

https://otter.ai/u/eg-ltfZpXu6OHBphoCJ16fHKIEQ?utm_source=copy_url

####

Chat GPT4

Subject: Detailed Summary of Conversation between Dr. Robert Califf, Outgoing FDA Commissioner, and Esther Krofah, Milken Institute Health Summit – November 13, 2024

---

Overview

The November 13, 2024, Milken Health Summit hosted a conversation between Dr. Robert Califf, outgoing FDA Commissioner, and Esther Krofah, Executive Vice President of Health at the Milken Institute. This discussion provided insights into Dr. Califf’s reflections on his tenure, challenges he faced, and his perspectives on FDA's future regulatory responsibilities, including areas such as food safety, medical product innovation, AI in healthcare, and diversity in clinical trials.

Key Discussion Points

1. Opening Remarks and Background of Califf’s Tenure

• Krofah opened by acknowledging Dr. Califf's “two tours of duty” as FDA Commissioner, specifically highlighting his leadership during crises, such as the Abbott infant formula recall.
• Califf shared that this crisis occurred on his first day back, emphasizing the immediate need for response and crisis management. His leadership has been marked by rapid adjustments to unexpected challenges.

2. Califf’s Reflections on Legacy and Accomplishments

• FDA's Role in Food Safety: Califf discussed the major reorganization of FDA’s food division, a response to the growing complexity of food safety regulation. This reorganization involved approximately 8,000 staff, predominantly focused on inspections rather than nutrition—a limitation influenced by congressional budget allocations.
• Medical Product Innovation: On the medical product side, Califf highlighted FDA’s expanded focus on cross-department collaboration, especially in rare diseases. He noted the FDA’s essential role in balancing product innovation with safety, maintaining its global reputation as the “gold standard” for regulatory bodies.

3. Challenges in U.S. Healthcare Delivery and Innovation

• Califf expressed concern about the U.S.’s healthcare system, pointing out that the country’s innovative capacity does not translate effectively into accessible healthcare for all. The U.S. ranks last among high-income nations in healthcare access and outcomes, a concern he believes extends beyond FDA’s scope but requires multi-stakeholder action.

4. FDA’s Role in Artificial Intelligence (AI) Integration in Healthcare

• Califf articulated that FDA is prepared to oversee certain aspects of AI-driven medical advancements, particularly those related to molecular discovery and clinical trial design. He highlighted FDA’s expertise in assessing safety and efficacy in clinical settings.
• However, Califf identified AI decision support in healthcare delivery as an area that lacks robust monitoring. He advocated for an “ecosystem” approach where FDA guidelines support self-regulation, similar to how farms adhere to food safety standards between inspections. This ecosystem approach is essential for safely integrating generative AI into clinical environments, recognizing AI’s potential to dynamically improve patient care.

5. Evidence Generation and Post-Market Trials

• Califf discussed the need for evidence generation throughout a medical product's life cycle, emphasizing the importance of post-market data for real-world efficacy and safety evaluations. He referenced pragmatic trials, which involve broader patient demographics and lower costs, as an optimal way to address questions not fully explored in pre-market trials.
• FDA’s partnership with CMS (Centers for Medicare & Medicaid Services) was highlighted as a positive example of collaboration to set post-market evidence standards. This partnership is essential for evaluating long-term product effectiveness and could drive future regulatory processes that combine pre- and post-market insights.

6. Challenges in Diversity and Accessibility in Clinical Trials

• Diversity Action Plans: Califf emphasized the need for comprehensive diversity action plans across all stages of drug development, not limited to phase III trials. He explained that these plans should ensure the representation of the populations that will eventually use the treatments.
• Structural Bias in Healthcare: Califf recognized that clinical trials alone cannot correct structural healthcare disparities, especially along socioeconomic and rural-urban divides. He noted that, with clinical trials becoming smaller, capturing a representative sample of global populations remains an immense challenge. This issue requires innovative solutions and expanded use of digital interfaces to reach underrepresented populations, especially in rural areas with limited access to specialized care.

7. Public Health, FDA’s Role, and Societal Perceptions

• Califf addressed the heightened scrutiny public health agencies face, particularly during crises like the COVID-19 pandemic. He argued that successful public health often goes unnoticed because crises are averted. Nonetheless, he underscored that the U.S. healthcare system has notable deficiencies, such as poor diet and declining life expectancy, that require urgent public health reform beyond FDA’s regulatory duties.
• Dietary health was cited as a particularly concerning area, with Califf stressing that quick fixes like dietary supplements are not substitutes for healthier eating habits. He advocated for public health measures that promote sustainable, systemic changes to Americans' dietary behaviors.

8. Advice for Future FDA Leadership

• Executive Skillset: Califf advised future commissioners to emphasize executive capabilities, including active listening, collaboration, and crisis management. He cautioned against a purely prescriptive approach, urging future leaders to remain adaptable to diverse challenges.
• Commitment to Evidence-Based Decisions: Califf recommended a strong commitment to evidence generation and analysis as central to sound FDA decision-making.
• Distinguishing Science from Politics: While recognizing the influence of political factors on FDA policy, Califf suggested that individual product decisions should remain grounded in scientific evidence. He explained that while policy affecting broad categories of products may involve political considerations, decisions on specific products should be evidence-based to maintain FDA’s integrity.

Conclusion

This dialogue showcased Dr. Califf’s reflections on FDA’s progress and areas needing continued focus, particularly as they relate to public health, regulatory science, AI integration, and clinical trial diversity. His insights highlight FDA’s pivotal role in supporting innovation while safeguarding public health, as well as the necessity of an ecosystem-based approach in the evolving regulatory landscape. The conversation ended with gratitude for Califf’s service and contributions, underscoring the complex, multi-faceted role FDA plays in modern healthcare.